
PTCT Valuation
PTC Therapeutics Inc
- Overview
- Forecast
- Valuation
- Earnings
PTCT Relative Valuation
PTCT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PTCT is overvalued; if below, it's undervalued.
Historical Valuation
PTC Therapeutics Inc (PTCT) is now in the Fair zone, suggesting that its current forward PS ratio of 4.72 is considered Fairly compared with the five-year average of -10.59. The fair price of PTC Therapeutics Inc (PTCT) is between 39.70 to 68.62 according to relative valuation methord.
Relative Value
Fair Zone
39.70-68.62
Current Price:50.40
Fair
-13.23
PE
1Y
3Y
5Y
Trailing
Forward
6.25
EV/EBITDA
PTC Therapeutics Inc. (PTCT) has a current EV/EBITDA of 6.25. The 5-year average EV/EBITDA is 13.39. The thresholds are as follows: Strongly Undervalued below -372.98, Undervalued between -372.98 and -179.80, Fairly Valued between 206.58 and -179.80, Overvalued between 206.58 and 399.77, and Strongly Overvalued above 399.77. The current Forward EV/EBITDA of 6.25 falls within the Historic Trend Line -Fairly Valued range.
-26.55
EV/EBIT
PTC Therapeutics Inc. (PTCT) has a current EV/EBIT of -26.55. The 5-year average EV/EBIT is -11.33. The thresholds are as follows: Strongly Undervalued below -59.38, Undervalued between -59.38 and -35.35, Fairly Valued between 12.69 and -35.35, Overvalued between 12.69 and 36.71, and Strongly Overvalued above 36.71. The current Forward EV/EBIT of -26.55 falls within the Historic Trend Line -Fairly Valued range.
4.62
PS
PTC Therapeutics Inc. (PTCT) has a current PS of 4.62. The 5-year average PS is 4.49. The thresholds are as follows: Strongly Undervalued below 1.11, Undervalued between 1.11 and 2.80, Fairly Valued between 6.18 and 2.80, Overvalued between 6.18 and 7.87, and Strongly Overvalued above 7.87. The current Forward PS of 4.62 falls within the Historic Trend Line -Fairly Valued range.
-21.29
P/OCF
PTC Therapeutics Inc. (PTCT) has a current P/OCF of -21.29. The 5-year average P/OCF is -33.20. The thresholds are as follows: Strongly Undervalued below -262.22, Undervalued between -262.22 and -147.71, Fairly Valued between 81.31 and -147.71, Overvalued between 81.31 and 195.82, and Strongly Overvalued above 195.82. The current Forward P/OCF of -21.29 falls within the Historic Trend Line -Fairly Valued range.
6.31
P/FCF
PTC Therapeutics Inc. (PTCT) has a current P/FCF of 6.31. The 5-year average P/FCF is 30.87. The thresholds are as follows: Strongly Undervalued below -460.62, Undervalued between -460.62 and -214.88, Fairly Valued between 276.62 and -214.88, Overvalued between 276.62 and 522.37, and Strongly Overvalued above 522.37. The current Forward P/FCF of 6.31 falls within the Historic Trend Line -Fairly Valued range.
PTC Therapeutics Inc (PTCT) has a current Price-to-Book (P/B) ratio of -18.91. Compared to its 3-year average P/B ratio of -7.30 , the current P/B ratio is approximately 158.90% higher. Relative to its 5-year average P/B ratio of 92.69, the current P/B ratio is about -120.40% higher. PTC Therapeutics Inc (PTCT) has a Forward Free Cash Flow (FCF) yield of approximately 19.54%. Compared to its 3-year average FCF yield of -6.10%, the current FCF yield is approximately -420.56% lower. Relative to its 5-year average FCF yield of -6.80% , the current FCF yield is about -387.26% lower.
-21.02
P/B
Median3y
-7.30
Median5y
92.69
19.72
FCF Yield
Median3y
-6.10
Median5y
-6.80
Competitors Valuation Multiple
The average P/S ratio for PTCT's competitors is 6.48, providing a benchmark for relative valuation. PTC Therapeutics Inc Corp (PTCT) exhibits a P/S ratio of 4.62, which is -28.68% above the industry average. Given its robust revenue growth of 459.73%, this premium appears sustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PTCT increased by 50.49% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 210.12M to 1.18B.
The secondary factor is the P/E Change, contributed -140.17%to the performance.
Overall, the performance of PTCT in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch

DLO
Dlocal Ltd
10.400
USD
0.00%

CNXC
Concentrix Corp
55.000
USD
-0.56%

SNEX
StoneX Group Inc
97.810
USD
+0.01%

ASH
Ashland Inc
52.350
USD
-1.19%

AMBA
Ambarella Inc
67.610
USD
0.00%

STR
Sitio Royalties Corp
17.910
USD
-1.32%

FORM
FormFactor Inc
29.420
USD
-14.53%

REZI
Resideo Technologies Inc
28.600
USD
+0.28%

ATHM
Autohome Inc
26.210
USD
-3.00%

RYTM
Rhythm Pharmaceuticals Inc
84.660
USD
0.00%
FAQ

Is PTC Therapeutics Inc (PTCT) currently overvalued or undervalued?
PTC Therapeutics Inc (PTCT) is now in the Fair zone, suggesting that its current forward PS ratio of 4.72 is considered Fairly compared with the five-year average of -10.59. The fair price of PTC Therapeutics Inc (PTCT) is between 39.70 to 68.62 according to relative valuation methord.

What is PTC Therapeutics Inc (PTCT) fair value?

How does PTCT's valuation metrics compare to the industry average?

What is the current P/B ratio for PTC Therapeutics Inc (PTCT) as of Jul 31 2025?

What is the current FCF Yield for PTC Therapeutics Inc (PTCT) as of Jul 31 2025?

What is the current Forward P/E ratio for PTC Therapeutics Inc (PTCT) as of Jul 31 2025?
